Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 183 for lung disease

Edit search filters
  1. A Study to Evaluate Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility

    Jacksonville, FL

  2. Home-based Pulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease

    Rochester, MN

  3. Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

    Rochester, MN

  4. A Study to Evaluate the Long-Term Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

    Rochester, MN

  5. Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (MACS-2)

    Rochester, MN

  6. PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease

    Scottsdale/Phoenix, AZ

  7. Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD)

  8. Mesenchymal Stem Cell Therapy for Lung Rejection

  9. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

    Rochester, MN

  10. A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

    Rochester, MN

.

Mayo Clinic Footer